Ultimately the committee must decide who is considered at high enough risk for an extra dose. Data provided by Pfizer and the ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

Moderna’s latest clinical update centers on a long‑term extension of its cytomegalovirus (CMV) vaccine program, officially titled “A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the ...

If approved, immunocompromised people would be able to get the booster dose before it is offered to the public at large. Companies like Moderna and Pfizer are pushing for the third shot because they ...

ETHealthworld.com brings latest nasal spray news, views and updates from all top sources for the Indian Health industry.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer (PFE) stock is in focus as the firm gets FDA priority review for its marketing application seeking a label expansion ...

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...